Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCbHP vs ECHP-THP in HER2+ Breast Cancer
NCT05474690Phase 3Withdrawn
- Sponsor
- Henan Cancer Hospital
- Start
- May 2022
- Primary completion
- Mar 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of carboplatin, epirubicin, cyclophosphamide in HER2-positive breast cancer, sponsored by Henan Cancer Hospital. Planned start May 2022; status: withdrawn.
02
Drugs
carboplatinepirubicincyclophosphamide
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05474690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05474690.